The methods showed a good and significant correlation (r = 0.74, P < 0.001) when perfusion across all the measured regions of the lung were evaluated and was maintained when the evaluation was done by lung zones: r = 0.84 (P < 0.001), r = 0.69 (P < 0.001), and r = 0.76 (P < 0.001) for apical, medial, and basal zones, respectively.
It is important to consider how long specific treatments maintain clinical remission when evaluating the effectiveness of a treatment.
First, using a clinical FFR cutoff of 0.80 as a reference, we evaluated whether the diagnostic performance and optimal cutoff of iFR are maintained, when compared with offline studies.
However, do they maintain this same standard when evaluating their own treatments?
Doctors like to point to the "impressive" efficacy of their treatments in real serious diseases, like cancer, and doctors (and drug companies) are emphatic about asserting that anyone or any company that says (or even suggests) that they have a treatment that might help people with cancer are "quacks". However, do they maintain this same standard when evaluating their own treatments?
These compilations are most useful for maintaining a historic perspective when evaluating the carcinogenicity of contemporary experiments.
Larger studies are necessary to maintain acceptable alpha error rates when evaluating higher median TTP and RR values of interest.
It is important that physicians maintain an index of suspicion when evaluating whether adherence is a factor in suboptimal responses in TKI-treated patients.
Clinicians should maintain a high degree of suspicion when evaluating patients presenting with symptoms of airway compression whose mechanism of injury is consistent with those associated with retropharyngeal hematomas because these initial symptoms may progress rapidly to lethal airway obstruction.
Since this tumor is responsive to methotrexate and other chemotherapy treatment, it is important to maintain a high index of suspicion when evaluating patients with non-focal neurologic manifestations and diffuse imaging abnormalities.
